Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03006367 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD
A Phase 1 study of Attention Deficit Disorder With Hyperactivity, sponsored by Aevi Genomic Medicine, LLC, a Cerecor company.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 3
- Study locations
NCT03006367 is a Phase 1 study of Attention Deficit Disorder With Hyperactivity that has completed, run by Aevi Genomic Medicine, LLC, a Cerecor company. The registered enrollment target is 32 participants, below the 354-participant average among 20 other Attention Deficit Disorder With Hyperactivity trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT03006367, a Phase 1 study of Attention Deficit Disorder With Hyperactivity, has completed, sponsored by Aevi Genomic Medicine, LLC, a Cerecor company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a open-label, single ascending dose, pharmacokinetic, and tolerability study of NFC-1 in Children and Adolescents (Ages 6-17 Years) with ADHD.
Conditions Studied
Interventions
- DRUG NFC-1 100 mg
- DRUG NFC-1 200 mg
- DRUG NFC-1 400 mg
- DRUG NFC-1 800 mg
Study Locations (3)
Florida
- Meridien Research, Inc. - Maitland
- QPS-MRA, LLC (Miami Research Associates) - Miami
Nevada
- Center for Psychiatry and Behavioral Medicine - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2017-01-07 |
| Est. Completion | 2017-03-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03006367
The ClinicalTrials.gov registry entry for NCT03006367 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 354-participant average among 20 other Attention Deficit Disorder With Hyperactivity trials with a reported enrollment target (91% lower). The listed sponsor is Aevi Genomic Medicine, LLC, a Cerecor company, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Attention Deficit Disorder With Hyperactivity appearing as the primary indexed condition, and to 4 interventions - of which NFC-1 100 mg is the first listed.
NCT03006367 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Florida, Nevada.
Frequently Asked Questions
What is clinical trial NCT03006367 about?
NCT03006367 is a clinical study titled "Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD". This is a open-label, single ascending dose, pharmacokinetic, and tolerability study of NFC-1 in Children and Adolescents (Ages 6-17 Years) with ADHD.
What is the current status of trial NCT03006367?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2017-01-07. Estimated completion is 2017-03-06.
What conditions does trial NCT03006367 study?
This clinical trial studies the following conditions: Attention Deficit Disorder With Hyperactivity.
What interventions are being tested in trial NCT03006367?
The interventions under investigation include: NFC-1 100 mg (DRUG), NFC-1 200 mg (DRUG), NFC-1 400 mg (DRUG), NFC-1 800 mg (DRUG).
Who is sponsoring clinical trial NCT03006367?
This trial is sponsored by Aevi Genomic Medicine, LLC, a Cerecor company, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03006367 being conducted?
This trial has 3 study locations across Florida, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Disorder With Hyperactivity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse
COMPLETED · Phase 1
-
Home-based Transcranial Direct Current Stimulation (tDCS) for Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)
RECRUITING · NA
-
Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers
ACTIVE NOT RECRUITING
-
Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD
COMPLETED · Phase 2
-
Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
COMPLETED · NA
-
TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.